SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing intense volatility and downward pressure after Marvell canceled its purchase orders, citing a confidentiality breach caused by the CFO's recent public commentary. Community members are deeply divided between long-term bulls who believe in the company's underlying photonics technology and frustrated investors who are calling for management accountability and questioning the firm's transparency after news of the cancellation was delayed.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors grapple with persistent downward pressure and concerns over potential dilution, despite the company's focus on its upcoming mid-size vehicle platform and continued financial backing from key institutional partners. Community sentiment remains sharply divided between long-term bulls highlighting the company's technical product advantages and skeptics who fear further share price erosion and the threat of bankruptcy or restructuring.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently surging to fresh all-time highs as traders and institutional investors express strong bullish sentiment regarding its dominant role in the AI infrastructure supply chain. The community is actively debating the stock's massive market capitalization and momentum, with many discussing the potential for further breakout growth while keeping a close watch on key technical levels.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca (ERAS) is facing significant market volatility following an 8-K filing that disclosed a Grade 5 fatality, raising investor concerns regarding potential FDA clinical holds and long-term asset viability. Community sentiment is deeply polarized, with critics warning of toxic data and potential bankruptcy, while some long-term holders dismiss the reaction as an over-correction and advocate for buying the dip.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending as investors bet on the commercial viability of its proprietary Perkinamine polymer technology, which is seen as a key solution for high-speed, energy-efficient data center and AI connectivity. Community discussions are heavily focused on the company's potential to displace legacy materials in hyperscale environments, with significant excitement surrounding upcoming industry milestones and partnerships.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently at the center of intense market attention following the release of positive Phase 3 data for its gene-editing therapy and the initiation of a rolling FDA filing. The stock is experiencing extreme volatility as retail investors debate the significance of the clinical results and the implications of a subsequent common stock offering, while the community remains sharply divided over the potential for a short squeeze given the high short interest.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group Inc. is trending as investors debate its long-term potential in AI infrastructure and data center projects against concerns regarding management transparency and capital structure. The community is actively discussing the stock's recent bullish momentum and potential short squeeze, while highlighting recent partnerships in India as a key catalyst for growth.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors react to a significant revenue increase and a shift toward an 'Everything Home' operational model, fueling intense community debate over the company's turnaround viability. Discussion remains heavily polarized between bulls betting on management's integration of new retail and fintech assets and bears cautioning against persistent cash burn and equity dilution.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as the market reacts to the formal rescheduling of medical marijuana to Schedule III, a shift expected to provide significant tax relief by eliminating the Section 280E tax burden. Community discourse remains heavily focused on the company's dominant market share in Florida and anticipation that this regulatory milestone will pave the way for institutional capital and potential uplisting to major exchanges.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is trending following a massive definitive agreement to acquire Exact Sciences for approximately $23 billion, a strategic move to solidify its leadership in the multi-billion dollar cancer diagnostics and oncology market. Community discussions are highly polarized, with many investors debating the acquisition's long-term value and integration risks versus the potential for expanded market share in the rapidly growing precision oncology sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vestis Corporation (NYSE:VSTS) Receives Consensus Rating of "Strong Sell" from Analysts

Vestis Corporation (NYSE:VSTS - Get Free Report) has received an average recommendation of "Strong Sell" from the five analysts that are presently covering the firm, Marketbeat reports. Four equities...

Vestis (NYSE:VSTS) Sets New 52-Week High - Time to Buy?

Vestis (NYSE:VSTS) Hits New 1-Year High - Time to Buy...

JPMorgan Chase & Co. Has $736,000 Stock Holdings in Vestis Corporation $VSTS

JPMorgan Chase & Co. lessened its position in shares of Vestis Corporation (NYSE:VSTS - Free Report) by 76.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities...

Pacific Point Advisors LLC Grows Stake in Vestis Corporation $VSTS

Pacific Point Advisors LLC grew its position in Vestis Corporation (NYSE:VSTS - Free Report) by 603.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and...

Vestis Corporation $VSTS Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Vestis Corporation (NYSE:VSTS - Free Report) by 1,506.6% in the 4th quarter, according to its most recent disclosure with the Securities and...

Vestis Reaches Analyst Target Price

In recent trading, shares of Vestis Corp (Symbol: VSTS) have crossed above the average analyst 12-month target price of $7.81, changing hands for $7.82/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation...

Vestis Corporation (NYSE:VSTS) Given Consensus Recommendation of "Strong Sell" by Brokerages

Vestis Corporation (NYSE:VSTS - Get Free Report) has been given a consensus recommendation of "Strong Sell" by the five analysts that are currently covering the firm, MarketBeat.com reports. Four...

Invenomic Capital Management LP Has $5.81 Million Holdings in Vestis Corporation $VSTS

Invenomic Capital Management LP boosted its position in shares of Vestis Corporation (NYSE:VSTS - Free Report) by 158.3% in the third quarter, according to the company in its most recent 13F filing...

Vestis Corporation $VSTS Shares Bought by Private Management Group Inc.

Private Management Group Inc. lifted its stake in shares of Vestis Corporation (NYSE:VSTS - Free Report) by 6.1% during the 3rd quarter, according to the company in its most recent 13F filing with...

Medina Value Partners LLC Buys New Holdings in Vestis Corporation $VSTS

Medina Value Partners LLC purchased a new position in Vestis Corporation (NYSE:VSTS - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and...

Vestis Corp. engages in the B2B uniform and workplace supplies category. It operates through the United States and Canada geographical segments. It provides uniform services, and workplace supplies to North American customers from Fortune 500 companies to locally owned small businesses across a broad set of end markets. The company’s comprehensive service offering includes a full-service uniform rental program, cleanroom and other specialty garment processing, floor mats, towels, linens, managed restroom services, and first aid supplies. The company was founded on November 7, 2023 and is headquartered in Roswell, GA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.08	--	--	N/A
Q1 '26	$0.06	$0.10	57.90%	BEAT
Q4 '25	$0.06	$0.03	-47.67%	MISSED
Q3 '25	$0.05	-$0.01	-120.11%	MISSED
Q2 '25	$0.14	-$0.05	-135.10%	MISSED

VSTS
VESTIS CORPORATION

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest VSTS News

VSTSVESTIS CORPORATION